Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $70.00

Definium Therapeutics (NASDAQ:DFTX) had its price target boosted by HC Wainwright from $55.00 to $70.00 in a research report released on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other brokerages have also commented on DFTX. Robert W. Baird set a $37.00 price objective on shares of Definium Therapeutics in a report on Thursday, January 29th. Royal Bank Of Canada boosted their price target on Definium Therapeutics from $20.00 to $36.00 and gave the stock an “outperform” rating in a research note on Friday, January 23rd. Jefferies Financial Group started coverage on Definium Therapeutics in a report on Thursday, January 29th. They issued a “buy” rating and a $30.00 price target for the company. JonesTrading began coverage on Definium Therapeutics in a report on Tuesday, December 23rd. They set a “buy” rating and a $61.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Definium Therapeutics has a consensus rating of “Buy” and an average price target of $35.70.

Definium Therapeutics Stock Up 0.4%

Shares of NASDAQ:DFTX opened at $17.76 on Monday. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -8.34 and a beta of 2.56. The company has a 50 day moving average of $15.90 and a two-hundred day moving average of $12.99. Definium Therapeutics has a 52-week low of $4.70 and a 52-week high of $18.70. The company has a quick ratio of 6.29, a current ratio of 6.29 and a debt-to-equity ratio of 0.12.

Insider Activity at Definium Therapeutics

In other Definium Therapeutics news, CEO Robert Barrow sold 25,791 shares of the company’s stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $339,151.65. Following the sale, the chief executive officer owned 778,477 shares in the company, valued at $10,236,972.55. This represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Mark Sullivan sold 11,276 shares of Definium Therapeutics stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $148,279.40. Following the completion of the transaction, the insider owned 282,576 shares of the company’s stock, valued at approximately $3,715,874.40. The trade was a 3.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 42,667 shares of company stock valued at $561,071 over the last three months. 2.26% of the stock is owned by insiders.

Institutional Trading of Definium Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. boosted its holdings in shares of Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after buying an additional 2,003 shares during the period. BIT Capital GmbH acquired a new stake in Definium Therapeutics during the third quarter worth about $26,000. CWM LLC lifted its holdings in Definium Therapeutics by 67.4% in the second quarter. CWM LLC now owns 4,459 shares of the company’s stock worth $29,000 after acquiring an additional 1,796 shares during the last quarter. Fifth Third Bancorp boosted its stake in Definium Therapeutics by 5,593.2% in the third quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock valued at $40,000 after acquiring an additional 3,300 shares during the period. Finally, Sound Income Strategies LLC acquired a new position in Definium Therapeutics in the third quarter valued at approximately $46,000. 27.91% of the stock is owned by institutional investors and hedge funds.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.